Back to top
more

Achillion Pharmaceuticals, Inc. (ACHN)

(Delayed Data from NSDQ)

$2.96 USD

2.96
1,311,012

-0.05 (-1.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

by Zacks Equity Research

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

by Zacks Equity Research

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Sweta Killa headshot

5 Stocks That Pushed Russell 2000 ETF Higher

by Sweta Killa

Inside the best performing stocks of the Russell 2000 ETF.

Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

by Zacks Equity Research

Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.

Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

by Zacks Equity Research

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

by Sanghamitra Saha

Pharma sector wins in October, making these ETFs and stocks winners.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

by Sweta Killa

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

by Zacks Equity Research

Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

by Sweta Killa

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

by Zacks Equity Research

Key highlights of the past week include acquisition news, and regulatory and pipeline updates.

Alexion Gets FDA Approval for Label Expansion of Ultomiris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.

Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?

by Zacks Equity Research

During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.

Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

by Zacks Equity Research

Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Why Is Achillion (ACHN) Down 11.2% Since Last Earnings Report?

by Zacks Equity Research

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil

by Zacks Equity Research

Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.

Alexion's Ultomiris Receives EU Approval for PNH in Adults

by Zacks Equity Research

Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

Alexion Receives FDA Approval for Label Expansion of Soliris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

Alexion's sBLA for Ultomiris Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report?

by Zacks Equity Research

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?

by Zacks Equity Research

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Achillion Meets Enrollment Target in Kidney Disease Studies

by Zacks Equity Research

Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.